Physician profile
Marlon Burt
NPI 1871584144
$2,166.47
in general payments reported to CMS, 2019-2025
13 companies · $920 in 2025
The $920 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.75 · 2020: $18.40 · 2021: $39.82 · 2023: $414 · 2024: $722 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $581.87 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $543.34 | 2023-2025 | Cequa |
| Abbvie INC. | $238.25 | 2023-2025 | Lumigan |
| Tarsus Pharmaceuticals, INC. | $154.45 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $136.37 | 2025 | Tearcare System |
| Oyster Point Pharma, INC. | $123.59 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alcon Vision LLC | $108.19 | 2023-2025 | Tryptyr, Rocklatan, Eysuvis |
| Harrow Eye, LLC | $92.86 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $55.06 | 2021-2023 | |
| Rxsight INC | $42.93 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Rayner Intraocular Lenses Limited | $19.41 | 2024 | Rayone Spheric, Rayone Emv, Omidria |
| Coopervision INC. | $14.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlon Burt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.